

Accepted Manuscript

Palladium-Catalyzed Highly Regioselective 2-alkynylation of 2,x-Dihalopyridines

Bin Zhang, Rener Chen, Huaijiang Jiang, Qizhong Zhou, Fangli Qiu, Deman Han, Rongrong Li, Wenyuan Tang, Aiguo Zhong, Jie Zhang, Xiaochun Yu



PII: S0040-4020(16)30160-0

DOI: [10.1016/j.tet.2016.03.027](https://doi.org/10.1016/j.tet.2016.03.027)

Reference: TET 27567

To appear in: *Tetrahedron*

Received Date: 2 December 2015

Revised Date: 4 March 2016

Accepted Date: 8 March 2016


Please cite this article as: Zhang B, Chen R, Jiang H, Zhou Q, Qiu F, Han D, Li R, Tang W, Zhong A, Zhang J, Yu X, Palladium-Catalyzed Highly Regioselective 2-alkynylation of 2,x-Dihalopyridines, *Tetrahedron* (2016), doi: 10.1016/j.tet.2016.03.027.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Graphical Abstract

Palladium-Catalyzed Highly Regioselective
2-alkynylation of 2,x-Dihalopyridines

Bin Zhang, Rener Chen, Huaijiang Jiang, Qizhong Zhou*, Fangli Qiu, Deman Han, Rongrong Li,
Wenyuan Tang, Aiguo Zhong, Jie Zhang and Xiaochun Yu*





Pergamon

TETRAHEDRON

Palladium-Catalyzed Highly Regioselective 2-alkynylation of 2,x-Dihalopyridines

Bin Zhang,¹ Rener Chen,¹ Huaijiang Jiang,¹ Qizhong Zhou*,¹ Fangli Qiu,¹ Deman Han,¹ Rongrong Li,¹ Wenyuan Tang,¹ Aiguo Zhong,¹ Jie Zhang¹ and Xiaochun Yu*²

¹Department of Chemistry, Taizhou University, Taizhou 318000, China

²College of Chemistry and Materials Engineering, Wenzhou University, Wenzhou, China

Email address: qizhongzhou@tzc.edu.cn (Zhou); yuxiaochunyc@hotmail.com (Yu); tel: 86-576-88660177

Dedicated to Academician Xikui Jiang on the occasion of his 90th birthday and Professor Zhenchu Chen on the occasion of his 80th birthday

Abstract—2,4-Dibromopyridines reacted with arylacetylenes, catalyzed by $\text{Pd}(\text{CF}_3\text{COO})_2/\text{CuI}/\text{PPh}_3$ in the presence of $\text{i-Pr}_2\text{NH}$ in CH_3CN at reflux for 24 hours, to afford 2-alkynylpyridines in good to high yields, while 2,3- and 2,5-Dihalopyridines reacted with arylacetylenes, catalyzed by $\text{Pd}(\text{OAc})_2/\text{CuI}/\text{PPh}_3$ in the presence of $\text{i-Pr}_2\text{NH}$ in CH_3CN at reflux for 24 hours, to afford 2-alkynylpyridines in good to high yields.

© 2016 Elsevier Science. All rights reserved

1 Introduction

Pyridines are significant components of many drugs and natural products.^[1-3] There are more than 15617 substituted 2-alkynylpyridines in database of SciFinder. Substituted 2-alkynylpyridines are found in a wide range of anti-inflammatory agents and antitumor agents,^[4] and AMPA receptors, dopamine receptors, NMDA receptors and metabotropic glutamate receptors.^[5] (Figure 1). Substituted 2-alkynylpyridines can be prepared by Sonogashira coupling from 2,x-dihalopyridines and alkynes using palladium catalysis. Nowadays, palladium catalysis catch so much attention in organic synthesis.^[6] Previously, we have reported the copper-catalyzed highly regioselective 2-aryloxylation of 2,x-dihalopyridines,^[7] and a highly regioselective and efficient palladium-catalyzed arylation of 2,x-dibromopyridines.^[8] Herein, we describe a highly regioselective and efficient palladium-catalyzed 2-alkynylation of 2,x-dihalopyridines.





Figure 1. The substituted 2-pyridyl motif is found in many important small molecules.

2 Results and Discussion

First, a set of experiments was performed using 2,4-dibromopyridine and phenylacetylene as the model substrates in the presence of different ligands or bases in different temperatures to explore the optimized reaction conditions (Table 1). In DME with $\text{PdCl}_2(\text{PPh}_3)_2$ as catalyst and Et_3N as base, the reaction afforded **3a**, **A** and **B** in 50%, 6% and 0% isolated yields, respectively (entry 4), while in MeCN a better selectivity was achieved (entry 8). Encouraged by these results, we investigated different palladium catalysis system and found better selectivity can be achieved under conditions listed in entry 9. In MeCN/EtOH (2:1) at 50 °C, the three products were obtained in 80%, 2% and 0% yields, respectively (entry 18).

In the end, we thus established the optimized conditions for this reaction: $\text{Pd}(\text{CF}_3\text{COO})_2/\text{PPh}_3$ as the catalysis system, i- Pr_2NH as the base, CH_3CN as the solvent and at reflux.

Table 1: Palladium-catalyzed 2-alkynylation of 2,4-dibromopyridine with phenylacetylene: parametric study.^[a,b]





entry	catalyst	base	solvent	T/°C	Yield% (3a:A:B)
1	$\text{PdCl}_2(\text{PPh}_3)_2$	Et_3N	toluene	reflux	51:18: 0
2	$\text{PdCl}_2(\text{PPh}_3)_2$	Et_3N	dioxane	reflux	21: 10: 0
3	$\text{PdCl}_2(\text{PPh}_3)_2$	Et_3N	DMF	110	20: 21: 0
4	$\text{PdCl}_2(\text{PPh}_3)_2$	Et_3N	DME	reflux	50: 6: 0
5	$\text{PdCl}_2(\text{PPh}_3)_2$	Et_3N	CHCl_3	reflux	60: 5: 9
6	$\text{PdCl}_2(\text{PPh}_3)_2$	Et_3N	MeOH	reflux	59:12: 25
7	$\text{PdCl}_2(\text{PPh}_3)_2$	Et_3N	DMSO	110	46: 3: 12
8	$\text{PdCl}_2(\text{PPh}_3)_2$	Et_3N	CH_3CN	reflux	65: 7: 0
9	$\text{Pd}(\text{OAc})_2/\text{PPh}_3$	Et_3N	CH_3CN	reflux	67: 2: 2
10	$\text{PdCl}_2/\text{PPh}_3$	Et_3N	CH_3CN	reflux	63: 6: 9
11	$\text{Pd}(\text{OAc})_2/\text{PPh}_3$	i- Pr_2NH	CH_3CN	reflux	73: 4: 5
12	$\text{Pd}(\text{OAc})_2/\text{PPh}_3$	K_2CO_3	CH_3CN	reflux	63: 6: 8
13	$\text{Pd}(\text{OAc})_2/\text{PPh}_3$	Cs_2CO_3	CH_3CN	reflux	60: 6: 12
14	$\text{Pd}(\text{OAc})_2/\text{PPh}_3$	K_3PO_4	CH_3CN	reflux	64: 4: 13
15	$\text{Pd}(\text{OAc})_2/\text{PPh}_3$	KOAc	CH_3CN	reflux	61: 3: 11
16	$\text{Pd}(\text{OAc})_2/\text{PPh}_3$	KOH	CH_3CN	reflux	40: 7: 4
17	$\text{Pd}(\text{OAc})_2/\text{PPh}_3$	CsOAc	CH_3CN	reflux	39: 10: 5
18 ^c	$\text{Pd}(\text{OAc})_2/\text{PPh}_3$	i- Pr_2NH	CH_3CN	reflux	80: 2: 0
19	$\text{Pd}(\text{OAc})_2/\text{PPh}_3$	i- Pr_2NH	65	70: 2: 5	
20	$\text{Pd}(\text{OAc})_2/\text{PPh}_3$	i- Pr_2NH	30	64: 0: 8	
21	$\text{Pd}(\text{CF}_3\text{COO})_2/\text{PPh}_3$	i- Pr_2NH	CH_3CN	reflux	84: 3: 0

The bold signifies the best reaction condition.

[a] Reaction conditions: **1a** (0.5 mmol), **2a** (0.6 mmol), [Pd] (5 mol%), ligand (10 mol%), CuI (5 mol%), base (1 mmol), 24h. [b] isolated yield. [c] **1a** (1 mmol), **2a** (0.5 mmol), [Pd] (5 mol%), ligand (10 mol%), CuI (5 mol%), base (1 mmol), 24h.

With the optimized reaction condition available, the scope of the reaction was then investigated (Table 2). It can be found that substituted phenylacetyles generally afforded products (**3a-3g**, **3j-3n**, **3r-3v**, **3y-3z**) in good to high yields (74–94%). In contrast, trimethylsilyl-substituted acetylene, hexyne and propargyl alcohol gave mild yields (43–70%, **3h-3i**, **3o-3q**, **3w-3x**) due to low conversion. Clearly, the new methodology has the advantages of higher regioselectivity, higher yields, more generality, simpler and cheaper catalyst system.⁹

Table 2: Scope of Pd-catalyzed 2-alkynylation of 2,x-dihalopyridines.^[a,b]



entry	1	2	Products	Yield (%)
1	1a	2a	3a	84
2	1a	2b	3b	80
3	1a	2c	3c	82
4	1a	2d	3d	81
5	1a	2e	3e	77
6	1a	2f	3f	74
7	1a	2g	3g	78
8 ^c	1a	2h	3h	43
9 ^c	1a	2i	3i	55
10 ^d	1b	2a	3j	91
11 ^d	1b	2b	3k	85
12 ^d	1b	2c	3l	83
13 ^d	1b	2f	3m	80
14 ^d	1b	2g	3n	83

15 ^c	1b	2h		3o	52
16 ^c	1b	2i		3p	58
17 ^c	1b	2j		3q	61
18 ^d	1c	2a		3r	94
19 ^d	1c	2d		3s	85
20 ^d	1c	2e		3t	85
21 ^d	1c	2f		3u	81
22 ^d	1c	2g		3v	81
23 ^c	1c	2i		3w	68
24 ^c	1c	2j		3x	70
25 ^d	1d	2a		3y	90
26 ^d	1e	2a		3z	84
27 ^d	1f	2a		3z1	88
28 ^d	1g	2a		3z2	82
29 ^d	1h	2a		3z3	76

[a] Reaction conditions: dibromopyridine (1 mmol), phenylacetylene (0.5 mmol), Pd(CF₃COO)₂ (5 mol%), PPh₃ (10 mol%), CuI (5 mol%), i-Pr₂NH (1 mmol), CH₃CN, 24h. [b] Isolated yield. [c] dibromopyridine (0.5 mmol), phenylacetylene (0.75 mmol), Pd(OAc)₂ (5 mol%), PPh₃ (10 mol%), CuI (5 mol%), i-Pr₂NH (1 mmol), CH₃CN, 24h. [d] dibromopyridine (0.5 mmol), phenylacetylene (0.6 mmol), Pd(OAc)₂ (5 mol%), PPh₃ (10 mol%), CuI (5 mol%), i-Pr₂NH (1 mmol), CH₃CN, 24h.

Why the regioselectivity is so high for the alkynylation of 2,3-, 2,5- and 2,4-dihalopyridines? We can explain that the 2-halo of 2,x-dihalopyridines is more reactive than the 4-halo, 5-halo and 3-halo of 2,x-dihalopyridines.^[7-12]

3 Conclusion

In summary, we have described a highly regioselective approach to halo-2-alkynylpyridines which involves palladium-catalyzed direct 2-alkynylation of 2,4-, 2,5-, and 2,3-dihalopyridines in high yields. Step-by-step coupling

reaction of other dihalopyridines is being investigated and the results will be reported in due course.

4 Experimental Section

Typical procedure for the 2-alkynylation of 2,4-dibromopyridine: 2,4-dibromopyridine (237 mg, 1.0 mmol), phenylacetylene (51 mg, 0.5 mmol), i-Pr₂NH (101 mg, 1.0 mmol), Pd(CF₃COO)₂ (16.6 mg, 5 mol%), PPh₃ (26 mg, 10 mol%) and CuI (9.5 mg, 5 mol%) were dissolved in CH₃CN (5 mL). The reaction was stirred at reflux under nitrogen atmosphere for 24 h and then cooled. The solid was filtered off and the filtrate was concentrated. The crude product was then dissolved in CH₂Cl₂ (10 mL) and the solution was washed with brine (10 mL), and dried over sodium sulfate. Upon evaporation, the resulting residue was subjected to column chromatography (petroleum ether/AcOEt, 200:1) to give **3a** (108 mg, 84%) as a colorless liquid.

Typical procedure for the 2-alkynylation of 2,5- and 2,3-dihalopyridines: 2,5-dibromopyridine (119 mg, 0.50 mmol), phenylacetylene (61 mg, 0.6 mmol), i-Pr₂NH (101 mg, 1.0 mmol), Pd(OAc)₂ (11 mg, 5 mol%), PPh₃ (26 mg, 10 mol%) and CuI (9.5 mg, 5 mol%) were dissolved in CH₃CN/CH₃OH (2:1, 6 mL). The solution was stirred at reflux under nitrogen atmosphere for 24 h and then cooled and the solid was filtered off. The filtrate was then concentrated and the resulting crude product was dissolved in CH₂Cl₂ (10 mL). The solution was washed with brine (10 mL), and dried over sodium sulfate. Upon removal of the solvent with a rotavapor, the resulting residue was subjected to column chromatography (petroleum ether/AcOEt, 200:1) to give the desired product **3i** (117 mg, 91%) as a white solid.

(1) 4-bromo-2-(phenylethyynyl)pyridine (**3a**)

3a: yellow liquid; ¹H NMR (CDCl₃, 400 MHz): 8.42 (d, *J* = 4 Hz, 1H), 7.71 (d, *J* = 4 Hz, 1H), 7.57-7.60 (m, 2H), 7.32-7.35 (m, 4H); ¹³C NMR (CDCl₃, 100 MHz): 150.4, 144.5, 132.7, 132.1, 130.2, 129.4, 128.5, 126.1, 121.8, 90.7, 87.5; HRMS (ESI) [M+H]⁺ calcd for C₁₃H₈BrN: 257.9913, found: 257.9912.

(2) 2-bromo-5-(phenylethyynyl)pyridine (**A**)

A: yellow solid, m.p. 49-50 °C; ¹H NMR (CDCl₃, 400 MHz): 8.35 (d, *J* = 4 Hz, 1H), 7.52-7.59 (m, 3H), 7.32-7.40 (m, 4H); ¹³C NMR (CDCl₃, 100 MHz): 149.9, 142.2, 134.1, 132.0, 129.7, 129.6, 128.6, 124.5, 121.6, 95.5, 85.3; HRMS (ESI) [M+H]⁺ calcd for C₁₃H₈BrN: 257.9913, found: 257.9912.

(3) 2,4-di(phenylethyynyl)pyridine (**B**)

B: yellow solid, m.p. 109-110 °C; ¹H NMR (CDCl₃, 400 MHz): 8.60 (d, *J* = 4 Hz, 1H), 7.53-7.64 (m, 5H), 7.31-7.37 (m, 7H); ¹³C NMR (CDCl₃, 100 MHz): 150.1, 143.6, 132.1, 131.9, 129.4, 129.1, 128.9, 128.5, 128.4, 124.5, 122.1, 121.9, 94.7, 89.9, 88.2, 86.2; HRMS (ESI) [M+H]⁺ calcd for C₂₁H₁₃N: 280.1121, found: 280.1120.

(4) 4-bromo-2-(4-methylphenylethynyl)pyridine (**3b**)
3b: yellow solid, m.p. 104-105 °C; ¹H NMR (CDCl₃, 400 MHz): 8.42 (d, *J* = 4 Hz, 1H), 7.70 (s, 1H), 7.49 (d, *J* = 8 Hz, 2H), 7.40 (dd, *J*₁ = 4 Hz, *J*₂ = 8 Hz, 1H), 7.18 (d, *J* = 8 Hz, 2H), 2.28 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz): 150.5, 144.7, 139.7, 132.6, 132.1, 130.1, 129.2, 125.9, 118.7, 91.0, 87.0, 21.6; HRMS (ESI) [M+H]⁺ calcd for C₁₄H₁₀BrN: 272.0069, found: 272.0072.

(5) 4-bromo-2-(4-methoxyphenylethynyl)pyridine (**3c**)
3c: yellow solid, m.p. 91-92 °C; ¹H NMR (CDCl₃, 400 MHz): 8.41 (d, *J* = 4 Hz, 1H), 7.68 (s, 1H), 7.54 (d, *J* = 8 Hz, 2H), 7.39 (dd, *J*₁ = 4 Hz, *J*₂ = 8 Hz, 1H), 6.89 (d, *J* = 8 Hz, 2H), 3.83 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz): 160.5, 150.5, 144.9, 133.8, 132.6, 129.9, 125.8, 114.2, 113.8, 91.1, 86.6, 55.3; HRMS (ESI) [M+H]⁺ calcd for C₁₄H₁₀BrNO: 288.0019, found: 288.0028.

(6) 4-bromo-2-(4-ethoxyphenylethynyl)pyridine (**3d**)
3d: yellow solid, m.p. 93-94 °C; ¹H NMR (CDCl₃, 400 MHz): 8.40 (d, *J* = 4 Hz, 1H), 7.67 (s, 1H), 7.50-7.53 (m, 2H), 7.38 (d, *J* = 4 Hz, 1H), 6.86-6.89 (m, 2H), 4.05 (q, *J* = 8 Hz, 2H), 1.42 (t, *J* = 8 Hz, 3H); ¹³C NMR (CDCl₃, 100 MHz): 159.9, 150.4, 144.9, 133.7, 132.6, 129.9, 125.7, 114.6, 113.6, 91.2, 86.5, 63.6, 14.7; HRMS (ESI) [M+H]⁺ calcd for C₁₅H₁₃BrNO: 302.0175, found: 302.0170.

(7) 4-bromo-2-(4-chlorophenylethynyl)pyridine (**3e**)
3e: yellow solid, m.p. 105-106 °C; ¹H NMR (CDCl₃, 400 MHz): 8.43 (d, *J* = 4 Hz, 1H), 7.71 (s, 1H), 7.52 (d, *J* = 4 Hz, 2H), 7.43 (d, *J* = 4 Hz, 1H), 7.35 (d, *J* = 4 Hz, 2H); ¹³C NMR (CDCl₃, 100 MHz): 150.6, 144.2, 135.5, 133.3, 132.7, 130.2, 128.9, 126.3, 120.2, 89.4, 88.3; EI [M]⁺ for C₁₃H₇ClBrN: 292.1; Anal. Calcd. for C₁₃H₇ClBrN: C 53.37; H 2.41; N 4.79; Found: C 53.55, H 2.48, N 4.77.

(8) 4-bromo-2-(4-bromophenylethynyl)pyridine (**3f**)
3f: yellow solid, m.p. 106-107 °C; ¹H NMR (CDCl₃, 400 MHz): 8.43 (d, *J* = 4 Hz, 1H), 7.71 (s, 1H), 7.51 (d, *J* = 8 Hz, 2H), 7.43-7.46 (m, 3H); ¹³C NMR (CDCl₃, 100 MHz): 150.6, 144.2, 133.5, 132.7, 131.8, 130.2, 126.4, 123.9, 120.7, 89.4, 88.4; HRMS (ESI) [M+H]⁺ calcd for C₁₃H₇Br₂N: 337.9018, found: 337.9021.

(9) 4-bromo-2-(2-methoxyphenylethynyl)pyridine (**3g**)
3g: yellow solid, m.p. 69-70 °C; ¹H NMR (CDCl₃, 400 MHz): 8.42 (d, *J* = 4 Hz, 1H), 7.73 (s, 1H), 7.55 (d, *J* = 8 Hz, 1H), 7.34-7.40 (m, 2H), 6.90-6.97 (m, 2H), 3.92 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz): 160.5, 150.5, 144.9, 134.1, 132.5, 130.9, 130.2, 125.9, 120.5, 111.1, 110.7, 91.7, 87.4, 55.8; HRMS (ESI) [M+H]⁺ calcd for C₁₄H₁₀BrNO: 288.0019, found: 288.0017.

(10) 4-bromo-2-trimethylsilyl ethynyl pyridine (**3h**)
3h: yellow liquid; ¹H NMR (CDCl₃, 400 MHz): 8.38 (d, *J* = 4 Hz, 1H), 7.64 (s, 1H), 7.41 (d, *J* = 4 Hz, 1H), 0.26 (s, 9H); ¹³C NMR (CDCl₃, 100 MHz): 150.8, 144.5, 133.0, 130.8,

126.8, 102.7, 97.1, 0.0; HRMS (ESI) [M+H]⁺ calcd for C₁₀H₁₂BrNSi: 253.9995, found: 253.9994.

(11) 4-bromo-2-(hexynyl)pyridine (**3i**)
3i: yellow liquid; ¹H NMR (CDCl₃, 400 MHz): 8.35 (d, *J* = 5.2 Hz, 1H), 7.55 (d, *J* = 1.6 Hz, 1H), 7.36 (dd, *J*₁ = 2.0 Hz, *J*₂ = 1.6 Hz, 1H), 2.45 (t, *J* = 7.2 Hz, 2H), 1.58-1.63 (m, 2H), 1.45-1.51 (m, 2H), 0.94 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (CDCl₃, 100 MHz): 150.5, 145.3, 132.7, 130.1, 125.9, 93.1, 79.6, 30.5, 22.3, 19.2, 13.8; HRMS (ESI) [M+H]⁺ calcd for C₁₁H₁₂BrN: 238.0231, found: 238.0226.

(12) 5-bromo-2-(phenylethynyl)pyridine (**3j**)
3j: yellow solid, m.p. 81-82 °C; ¹H NMR (CDCl₃, 400 MHz): 8.67 (d, *J* = 4 Hz, 1H), 7.81 (d, *J* = 8 Hz, 1H), 7.57-7.61 (m, 2H), 7.34-7.42 (m, 4H); ¹³C NMR (CDCl₃, 100 MHz): 151.2, 141.8, 138.9, 132.1, 129.2, 128.5, 128.1, 122.0, 120.0, 90.6, 87.7; HRMS (ESI) [M+H]⁺ calcd for C₁₃H₈BrN: 257.9913, found: 257.9912.

(13) 5-bromo-2-(4-methylphenylethynyl)pyridine (**3k**)
3k: yellow solid, m.p. 153-154 °C; ¹H NMR (CDCl₃, 400 MHz): 8.66 (s, 1H), 7.80 (dd, *J*₁ = 4 Hz, *J*₂ = 8 Hz, 1H), 7.48 (d, *J* = 8 Hz, 2H), 7.39 (d, *J* = 8 Hz, 1H), 7.17 (d, *J* = 8 Hz, 2H), 2.37 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz): 151.2, 142.0, 139.6, 138.8, 132.0, 129.2, 128.0, 119.7, 118.9, 90.9, 87.2, 21.6; HRMS (ESI) [M+H]⁺ calcd for C₁₄H₁₀BrN: 272.0069, found: 272.0065.

(14) 5-bromo-2-(4-methoxyphenylethynyl)pyridine (**3l**)
3l: yellow solid, m.p. 140-141 °C; ¹H NMR (CDCl₃, 400 MHz): 8.51 (s, 1H), 7.70 (s, 1H), 7.78 (dd, *J*₁ = 4 Hz, *J*₂ = 8 Hz, 2H), 7.53 (d, *J* = 8 Hz, 1H), 6.89 (d, *J* = 8 Hz, 2H), 3.83 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz): 160.4, 151.1, 142.2, 138.8, 133.7, 127.8, 119.5, 114.2, 114.0, 90.9, 86.8, 55.3; HRMS (ESI) [M+H]⁺ calcd for C₁₄H₁₀BrNO: 288.0019, found: 288.0018.

(15) 5-bromo-2-(4-bromophenylethynyl)pyridine (**3m**)
3m: yellow solid, m.p. 186-187 °C; ¹H NMR (CDCl₃, 400 MHz): 8.68 (d, *J* = 4 Hz, 1H), 7.82 (dd, *J*₁ = 4 Hz, *J*₂ = 8 Hz, 1H), 7.39-7.52 (m, 5H); ¹³C NMR (CDCl₃, 100 MHz): 151.3, 141.5, 138.9, 133.4, 131.8, 128.1, 123.7, 120.9, 120.2, 89.3, 88.8; HRMS (ESI) [M+H]⁺ calcd for C₁₃H₇Br₂N: 355.9018, found: 355.9015.

(16) 5-bromo-2-(2-methoxyphenylethynyl)pyridine (**3n**)
3n: yellow solid, m.p. 62-63 °C; ¹H NMR (CDCl₃, 400 MHz): 8.67 (d, *J* = 4 Hz, 1H), 7.91 (d, *J* = 8 Hz, 1H), 7.55 (d, *J* = 8 Hz, 1H), 7.43 (d, *J* = 8 Hz, 1H), 7.33-7.35 (m, 1H), 6.90-6.96 (m, 2H), 3.29 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz): 160.5, 151.1, 142.1, 138.7, 134.0, 130.8, 128.1, 120.5, 119.7, 111.2, 110.7, 91.7, 87.3, 55.8; HRMS (ESI) [M+H]⁺ calcd for C₁₄H₁₀BrNO: 288.0019, found: 288.0019.

(17) 5-bromo-2-trimethylsilyl ethynyl pyridine (**3o**)

3o: yellow solid, m.p. 46-47 °C; ¹H NMR (CDCl₃, 400 MHz): 8.55 (s, 1H), 7.70 (d, *J* = 8 Hz, 1H), 7.27 (d, *J* = 8 Hz, 1H), 0.20 (s, 9H); ¹³C NMR (CDCl₃, 100 MHz): 151.4, 141.8, 139.1, 128.6, 120.6, 103.0, 96.8, 0.0; HRMS (ESI) [M+H]⁺ calcd for C₁₀H₁₂BrNSi: 253.9995, found: 253.9992.

(18) 5-bromo-2-(hexynyl)pyridine (**3p**)

3p: yellow liquid; ¹H NMR (CDCl₃, 400 MHz): 8.59 (d, *J* = 2.0 Hz, 1H), 7.74 (dd, *J*₁ = 2.4 Hz, *J*₂ = 2.0 Hz, 1H), 7.26 (d, *J* = 8.4 Hz, 1H), 2.43 (t, *J* = 7.2 Hz, 2H), 1.58-1.65 (m, 2H), 1.45-1.51 (m, 2H), 0.94 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (CDCl₃, 100 MHz): 151.1, 142.6, 138.9, 128.0, 119.5, 92.8, 79.7, 30.5, 22.3, 19.3, 13.8; HRMS (ESI) [M+H]⁺ calcd for C₁₁H₁₂BrN: 238.0231, found: 238.0226.

(19) 5-bromo-2-(hydroxypropynyl)pyridine (**3q**)

3q: yellow solid, m.p. 112-113 °C; ¹H NMR (CDCl₃, 400 MHz): 8.62 (d, *J* = 2.0 Hz, 1H), 7.80 (dd, *J*₁ = 2.4 Hz, *J*₂ = 2.4 Hz, 1H), 7.32 (d, *J* = 8.0 Hz, 1H), 4.52 (s, 2H), 3.74 (brs, 1H); ¹³C NMR (CDCl₃, 100 MHz): 151.3, 141.3, 139.4, 128.3, 120.6, 89.8, 83.7, 51.3; HRMS (ESI) [M+H]⁺ calcd for C₈H₆BrNO: 211.9711, found: 211.9706.

(20) 3-bromo-2-(phenylethynyl)pyridine (**3r**)

3r: yellow solid, m.p. 44-45 °C; ¹H NMR (CDCl₃, 400 MHz): 8.55 (d, *J* = 4Hz, 1H), 7.92 (d, *J* = 8Hz, 1H), 7.62-7.67 (m, 2H), 7.35-7.39 (m, 3H), 7.12 (dd, *J*₁ = 4 Hz, *J*₂ = 8 Hz, 1H); ¹³C NMR (CDCl₃, 100 MHz): 148.3, 143.8, 139.8, 132.2, 129.4, 128.4, 123.9, 123.5, 122.0, 94.1, 87.5; HRMS (ESI) [M+H]⁺ calcd for C₁₃H₈BrN: 257.9913, found: 257.9917.

(21) 3-bromo-2-(4-ethoxyphenylethynyl)pyridine (**3s**)

3s: yellow solid, m.p. 92-93 °C; ¹H NMR (CDCl₃, 400 MHz): 8.53 (d, *J* = 4 Hz, 1H), 7.90 (d, *J* = 8 Hz, 1H), 7.57 (d, *J* = 8 Hz, 2H), 7.09 (dd, *J*₁ = 4 Hz, *J*₂ = 8 Hz, 1H), 6.88 (d, *J* = 8 Hz, 2H), 4.06 (q, *J* = 8 Hz, 2H), 1.42 (t, *J* = 8 Hz, 3H); ¹³C NMR (CDCl₃, 100 MHz): 160.0, 148.2, 144.1, 139.7, 133.8, 123.5, 123.1, 114.6, 113.8, 94.7, 86.6, 63.6, 14.7; HRMS (ESI) [M+H]⁺ calcd for C₁₅H₁₂BrNO: 302.0175, found: 302.0175.

(22) 3-bromo-2-(4-chlorophenylethynyl)pyridine (**3t**)

3t: yellow solid, m.p. 84-85 °C; ¹H NMR (CDCl₃, 400 MHz): 8.55 (d, *J* = 4 Hz, 1H), 7.93 (d, *J* = 4 Hz, 1H), 7.57 (d, *J* = 8Hz, 2H), 7.36 (d, *J* = 8 Hz, 2H), 7.35 (dd, *J*₁ = 4 Hz, *J*₂ = 4 Hz, 1H); ¹³C NMR (CDCl₃, 100 MHz): 148.3, 143.5, 139.9, 135.6, 133.4, 128.9, 123.9, 123.7, 120.5, 92.7, 88.3; EI [M]⁺ for C₁₃H₇ClBrN: 291; Anal. calcd for C₁₃H₇ClBrN: C 53.37; H 2.41; N 4.79; Found: C, 53.34; H, 2.42; N, 4.74.

(23) 3-bromo-2-(4-bromophenylethynyl)pyridine (**3u**)

3u: yellow solid, m.p. 75-76 °C; ¹H NMR (CDCl₃, 400 MHz): 8.55 (d, *J* = 4 Hz, 1H), 7.93 (d, *J* = 8 Hz, 1H), 7.49-7.53 (m, 4H), 7.14 (dd, *J*₁ = 4 Hz, *J*₂ = 8 Hz, 1H); ¹³C NMR (CDCl₃, 100 MHz): 148.4, 143.5, 139.9, 133.5, 131.8,

123.9, 123.7, 120.9, 92.8, 88.4; HRMS (ESI) [M+H]⁺ calcd for C₁₃H₇Br₂N: 355.9018, found: 355.9017.

(24) 3-bromo-2-(2-methoxyphenylethynyl)pyridine (**3v**)

3v: yellow solid, m.p. 101-102 °C; ¹H NMR (CDCl₃, 400 MHz): 8.55 (d, *J* = 4 Hz, 1H), 7.91 (d, *J* = 4 Hz, 1H), 7.61 (d, *J* = 4 Hz, 1H), 7.36 (t, *J* = 4 Hz, 1H), 7.10 (dd, *J*₁ = 4 Hz, *J*₂ = 8 Hz, 1H), 6.91-6.97 (m, 2H), 3.92 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz): 160.8, 148.2, 144.1, 139.8, 134.1, 130.9, 123.6, 123.3, 120.5, 111.3, 110.9, 91.4, 90.9, 55.9; HRMS (ESI) [M+H]⁺ calcd for C₁₄H₁₁BrNO: 288.0019, found: 288.0020.

(25) 3-bromo-2-(hexynyl)pyridine (**3w**)

3w: yellow liquid; ¹H NMR (CDCl₃, 400 MHz): 8.47 (dd, *J*₁ = 1.6 Hz, *J*₂ = 1.2 Hz, 1H), 7.87 (dd, *J*₁ = 1.6 Hz, *J*₂ = 1.2 Hz, 1H), 7.07 (q, *J* = 4.8 Hz, 1H), 2.52 (t, *J* = 6.8 Hz, 2H), 1.62-1.69 (m, 2H), 1.50-1.58 (m, 2H), 0.95 (t, *J* = 7.6 Hz, 3H); ¹³C NMR (CDCl₃, 100 MHz): 148.3, 144.3, 139.9, 123.6, 123.3, 96.7, 79.5, 30.4, 22.2, 19.4, 13.8; HRMS (ESI) [M+H]⁺ calcd for C₁₁H₁₂BrN: 238.0232, found: 238.0226.

(26) 3-bromo-2-(hydroxypropynyl)pyridine (**3x**)

3x: yellow solid, m.p. 106-107 °C; ¹H NMR (CDCl₃, 400 MHz): 8.51 (dd, *J*₁ = 1.2 Hz, *J*₂ = 1.6 Hz, 1H), 7.91 (dd, *J*₁ = 1.2 Hz, *J*₂ = 1.2 Hz, 1H), 7.14 (dd, *J*₁ = 4.4 Hz, *J*₂ = 4.8 Hz, 1H), 4.60 (s, 2H), 3.83 (brs, 1H); ¹³C NMR (CDCl₃, 100 MHz): 148.3, 143.3, 140.4, 124.2, 123.8, 93.3, 83.3, 51.4; HRMS (ESI) [M+H]⁺ calcd for C₈H₆BrNO: 211.9711, found: 211.9706.

(27) 5-bromo-4-methyl-2-(phenylethynyl)pyridine (**3y**)

3y: yellow solid, m.p. 59-60 °C; ¹H NMR (CDCl₃, 400 MHz): 8.63 (s, 1H), 7.57-7.60 (m, 2H), 7.34-7.41 (m, 4H), 2.40 (s, 3H), ¹³C NMR (CDCl₃, 100 MHz): 151.6, 147.2, 141.9, 132.0, 129.1, 129.0, 128.4, 122.8, 122.1, 90.0, 87.9, 22.1; HRMS (ESI) [M+H]⁺ calcd for C₁₄H₁₀BrN: 272.0069, found: 272.0069.

(28) 5-bromo-3-methyl-2-(phenylethynyl)pyridine (**3z**)

3z: yellow solid, m.p. 89-90 °C; ¹H NMR (CDCl₃, 400 MHz): ¹H NMR (CDCl₃, 400 MHz): 8.65 (s, 1H), 7.70 (s, 1H), 7.58-7.61 (m, 2H), 7.34-7.38 (m, 3H), 2.50 (s, 3H), ¹³C NMR (CDCl₃, 100 MHz): 148.4, 141.6, 139.4, 137.5, 132.0, 129.2, 128.5, 122.2, 119.6, 94.3, 86.7, 19.3; HRMS (ESI) [M+H]⁺ calcd for C₁₄H₁₀BrN: 272.0069, found: 272.0070.

(29) 3,5-dichloro-2-(phenylethynyl)pyridine (**3z1**)

3z1: yellow solid, m.p. 82-83 °C; ¹H NMR (CDCl₃, 400 MHz): 8.43 (d, *J* = 4Hz, 1H), 7.87 (s, 1H), 7.55-7.57 (m, 2H), 7.28-7.36 (m, 3H); ¹³C NMR (CDCl₃, 100 MHz): 146.3, 140.8, 138.2, 131.2, 129.8, 128.6, 127.5, 122.5, 120.7, 94.1, 85.6; HRMS (ESI) [M+H]⁺ calcd for C₁₃H₈Cl₂N: 248.0028, found: 248.0030.

(30) 3-chloro-5-bromo-2-(phenylethynyl) pyridine (**3z2**)

3z2: yellow solid, m.p. 93-94 °C; ¹H NMR (CDCl₃, 400 MHz): 8.47 (d, *J* = 4 Hz, 1H), 7.78 (d, *J* = 4 Hz, 1H), 7.63 (dd, *J*₁ = 4 Hz, *J*₂ = 8 Hz, 2H), 7.35-7.43 (m, 3H); ¹³C NMR (CDCl₃, 100 MHz): 146.9, 140.2, 136.2, 134.2, 132.2, 130.9, 129.6, 128.5, 121.7, 95.8, 85.1; HRMS (ESI) [M+H]⁺ calcd for C₁₃H₈BrClN: 291.9523, found: 291.9523.

(31) 3-chloro-5-trifluoromethyl-2-(phenylethynyl)pyridine (**3z3**)

3z3: yellow solid, m.p. 76-77 °C; ¹H NMR (CDCl₃, 400 MHz): 8.76 (d, *J* = 4 Hz, 1H), 7.99 (s, 1H), 7.65-7.68 (m, 2H), 7.38-7.46 (m, 3H); ¹³C NMR (CDCl₃, 100 MHz): 145.5, 144.5, 134.1, 133.8, 132.5, 130.0, 128.6, 126.0 (*q*, *J* = 30 Hz), 122.6 (*q*, *J* = 270 Hz), 121.2, 97.6, 85.3; HRMS (ESI) [M+H]⁺ calcd for C₁₄H₈ClF₃N: 282.0292, found: 282.0292.

Acknowledgment.

This work was supported by the Natural Science Foundation of China (21542010, 21506138, 21575097, 21501128) and Natural Science Foundation of Zhejiang Province (LY14B020012, LY14B030006 and LY15B030001), The public welfare analysis of science and technology plan projects of Zhejiang province (2015C37034).

References

- 1 Dong, H.; Latka, R. T.; Driver, T. G. *Org. Lett.* **2011**, *13*, 2726-2729.
- 2 Mousseau, J. J.; Bull, J. A.; Charette, A. B. *Angew. Chem. Int. Ed.* **2010**, *49*, 1115-1118.
- 3 Yuan, C.; Chang, C.; Siegel, D. *J. Org. Chem.* **2013**, *78*, 5647-5668.
- 4 a) Yu, B.; Ma, P.; Yuan, L.; Chen, D.; Yang, J. *Xenobiotica*, **2015**, *45*, 380-384; b) Hurley, M. P.; Stafford, R. S.; Lane, A. T. *JAMA Dermatology*, **2014**, *150*, 487-493; c) So, P.; Wang, G. Y.; Wang, K.; Chuang, M.; Chiueh, V. C.; Kenny, P. A.; Epstein, E. H., Jr. *Cancer Prevention Research*, **2014**, *7*, 407-417; d) Tang, J. Y.; Chiou, A. S.; Mackay-Wiggan, J. M.; Aszterbaum, M.; Chanana, A. M.; Lee, W.; Lindgren, J. A.; Raphael, M. A.; Thompson, B. J.; Bickers, D. R.; et al. *Cancer Prevention Res.* **2014**, *7*, 292-299.
- 5 a) Hagena, H.; Manahan-Vaughan, D. *J. Neurosci.* **2015**, *35*, 4999-5006; b) Fuzzati-Armentero, M.; Cerri, S.; Levandis, G.; Ambrosi, G.; Montepeloso, E.; Antoninetti, G.; Blandini, F.; Baqi, Y.; Mueller, C. E.; Volpini, R.; et al. *J. Neurochem.* **2015**, *134*, 740-747; c) Anighoro, A.; Graziani, D.; Bettinelli, I.; Cilia, A.; De Toma, C.; Longhi, M.; Mangiarotti, F.; Menegon, S.; Pirona, L.; Poggesi, E.; et al. *Bioorg. Med. Chem.* **2015**, *23*, 3040-3058; d) Chung, W.; Choi, S. Y.; Lee, E.; Park, H.; Kang, J.; Park, H.; Choi, Y.; Lee, D.; Park, S.; Kim, R.; et al. *Nature Neurosci.* **2015**, *18*, 435-443; e) Isojima, Y.; Nakajima, M.; Ukai, H.; Fujishima, H.; Yamada, R. G.; Masumoto, K.; Kiuchi, R.; Ishida, M.; Ukai-Tadenuma, M.; Minami, Y.; et al. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 15744-15749; f) Gregory, K. J.; Herman, E. J.; Ramsey, A. J.; Hammond, A. S.; Byun, N. E.; Stauffer, S. R.; Manka, J. T.; Jadhav, S.; Bridges, T. M.; Weaver, C. D.; et al. *J. Pharmacology and Experimental Therapeutics*, **2013**, *347*, 438-457; g) Bradley, S. J.; Langmead, C. J.; Watson, J. M.; Challiss, R. A. *J. Molecular Pharmacology*, **2011**, *79*(5), 874-885 h) Chen, Y.; Goudet, C.; Pin, J.; Conn, P. *J. Molecular Pharmacology*, **2008**, *73*, 909-918; h) Rodriguez, A. L.; Nong, Y.; Sekaran, N. K.; Alagille, D.; Tamagnan, G. D.; Conn, P. *J. Molecular Pharmacology*, **2005**, *68*, 1793-1802.
- 6 a) Shen, C.; Xia, H.; Yan, H.; Chen, X.; Ranjit, S.; Tan, D.; Lee, R.; Huang, K.; Zhang, P.; Liu, X. *Chem. Sci.* **2012**, *3*, 2388-2393; b) Shen, C.; Xu, J.; Yu, W.; Zhang, P. *Green Chem.* **2014**, *16*, 3007-3012; c) Shen, C.; Zhang, P.; Sun, Q.; Bai, S.; Andy Hor, T. S.; Liu, X. *Chem. Soc. Rev.* **2015**, *44*, 291-314; d) Shen, C.; Shen, H.; Yang, M.; Xia, C.; Zhang, P. *Green Chem.* **2015**, *17*, 225-230; e) Shen, H.; Shen, C.; Wang, A.; Zhang, P. *Cata. Sci. Tech.* **2015**, *5*, 2065-2071; f) Feng, Z.; Min, Q.; Zhao, H.; Gu, J.; Zhang, X. *Angew. Chem. Int. Ed.* **2015**, *54*, 1270-1274; g) Yu, Y.; He, G.; Zhang, X. *Angew. Chem. Int. Ed.* **2014**, *53*, 10457-10461; h) Feng, Z.; Min, Q.; Xiao, Y.; Zhan, B.; Zhang, X. *Angew. Chem. Int. Ed.* **2014**, *53*, 1669 -1673; i) Min, Q.; Yin, Z.; Feng, Z.; Guo, W.; Zhang, X. *J. Am. Chem. Soc.* **2014**, *136*, 1230-1233; j) Chen, Z.; He, C.; Yin, Z.; He, Y.; Zhang, X. *Angew. Chem. Int. Ed.* **2013**, *52*, 5813-5817; k) Fan, S.; Cheng, F.; Zhang, X. *Angew. Chem. Int. Ed.* **2011**, *50*, 5918-5923; l) Zhang, X.; Fan, S.; He, C.; Wan, X.; Min, Q.; Yang, J.; Jiang, Z. *J. Am. Chem. Soc.* **2010**, *132*, 4506-4507; m) He, C.; Fan, S.; Zhang, X. *J. Am. Chem. Soc.* **2010**, *132*, 12850-12852; n) Zhang, W.; Ren, S.; Zhang, J.; Liu, Y. *J. Org. Chem.* **2015**, *80*, 5973-5978; o) Zhang, W.; Zhang, J.; Ren, S.; Liu, Y. *J. Org. Chem.* **2014**, *79*, 11508-11516; p) Zhang, W.; Wu, D.; Zhang, J.; Liu, Y. *Eur. J. Org. Chem.* **2014**, 5827-5835; q) Zhang, W.; Lou, S. J.; Liu, Y.; Xu, Z. *J. Org. Chem.* **2013**, *78*, 5932-5948; r) Liu, Y.; Lou, S. J.; Xu, D. Q.; Xu, Z. *Chem. Eur. J.* **2010**, *16*, 13590-13593; s) Zhang, Q.; Yin, X.; Chen, K.; Zhang, S.; Shi, B. *J. Am. Chem. Soc.* **2015**, *137*, 8219-8226; t) Chen, K.; Shi, B. *Angew. Chem. Int. Ed.* **2014**, *53*, 11950-11954; u) Zhang, Q.; Chen, K.; Rao, W.; Zhang, Y.; Chen, F.; Shi, B. *Angew. Chem. Int. Ed.* **2013**, *52*, 13588-13592; v) Chen, F.; Zhao, S.; Hu, F.; Chen, K.; Zhang, Q.; Zhang, S.; Shi, B. *Chem. Sci.* **2013**, *4*, 4187-4192; w) Chen, K.; Hu, F.; Zhang, S.; Shi, B. *Chem. Sci.* **2013**, *4*, 3906-3911.
- 7 Zhou, Q.; Zhang, B.; Du, T.; Gu, H.; Ye, Y.; Jiang, H.; Chen, R. *Tetrahedron* **2013**, *69*, 327-333.
- 8 Zhou, Q.; Zhang, B.; Su, L.; Jiang, T.; Chen, R.; Du, T.; Ye, Y.; Shen, J.; Dai, G.; Han, D.; Jiang, H. *Tetrahedron*, **2013**, *69*, 10996-11003.
- 9 WO 2015/025019 by Boehringer Ingelheim GmbH

- 10 Sicre, C.; Alonso-Gómez, J.; Cid, M. M. *Tetrahedron* **2006**, *62*, 11063-11072.
- 11 Garcia, Y.; Schoenebeck, F.; Legault, C. Y.; Merlic, C. A.; Houk, K. N. *J. Am. Chem. Soc.* **2009**, *131*, 6632-6639.
- 12 Nolan, J. M.; Comins, D. L. *J. Org. Chem.* 2003, *68*, 3736-3738.